Rating Rationale
January 25, 2024 | Mumbai
EPIGRAL Limited
Long-term rating reaffirmed at 'CRISIL AA-/Stable'; 'CRISIL A1+' reassigned to short-term bank debt
 
Rating Action
Total Bank Loan Facilities RatedRs.1050 Crore
Long Term RatingCRISIL AA-/Stable (Reaffirmed)
Short Term RatingCRISIL A1+ (Reassigned)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL AA-/Stable’ rating on the long-term bank facilities of EPIGRAL Limited (Epigral; formerly known as Meghmani Finchem limited). CRISIL Ratings has also reassigned its CRISIL A1+ rating to the short term bank facility.

 

The rating continues to reflect Epigral’s healthy business risk profile supported by continued diversification in revenue streams, healthy operating margin and improving demand prospects. The rating also factors in a comfortable financial risk profile. These strengths are partially offset by the company’s high albeit reducing dependence on the intensely competitive chlor alkali industry, exposure to regulatory risks, vulnerability of operating margin to fluctuations in caustic soda prices and exposure to project implementation risks.

 

Revenue for the first half of fiscal 2024 witnessed 15% de-growth to Rs 933 crore from Rs 1088 crore during the corresponding period of the previous fiscal. The moderation in revenue was on account of the fall in realisations in key products owing to slow down in key end user industries and continued destocking of higher cost inventory. Revenue from chlor-alkali segment fell ~34% to Rs. 540 crores (58% of revenues) from Rs, 816 crore (~75% of total revenues) during H1FY23 owing to fall in realizations by ~40% even as volumes grew by ~6-7%. The derivative segment witnessed a growth of ~44% to ~Rs. 393 crores (42% of revenues) during H1FY24 from Rs. 272 crores (25% of revenues) in H1FY23 owing to commissioning of various chlorine downstream facilities. The share of chlor-alkali in total revenue has been steadily coming down from ~85% in fiscal 2019 to 58% during the first half of fiscal 2024 and is projected to further reduce over the medium term. Contribution from these downstream chlorine and hydrogen products along with healthy utilisation rates in existing facilities are expected to drive healthy revenue growth of 10-11% over the medium term. It might be noted that revenue for fiscal 2023 stood at Rs 2166 crore; year-on-year (y-o-y) growth of ~39% driven by a sharp increase in realisations across products, healthy utilisation levels (75-80%) and higher sales volumes.

 

Given the ongoing challenges, the company’s earnings before interest, tax, depreciation and amortisation (EBITDA) fell to Rs 203 crore during the first half of fiscal 2024 from Rs. 368 crore during the corresponding period previous fiscal. However, on a sequential basis, EBITDA has improved to Rs. 108 crore in the second quarter of this fiscal from Rs 95 crore in the first quarter because of expansion in gross margins by 100bps as larger part of high cost inventory was cleared off during Q1. The margins are expected to sustain at 23-25% over the medium term with ramp up in sales of new products like Chlorinated Polyvinyl Chloride (CPVC) and Epichlorohydrin (ECH).

 

The financial risk profile is comfortable driven by strong capital structure and healthy debt protection metrics. Networth stood at ~Rs 1105 crore with gearing at 0.86 time as on September 30, 2023. Despite ongoing capex, debt protection metrics such as interest cover was 5.2 times in the first half of fiscal 2024.  Furthermore, these metrics are expected to steadily improve over the medium term with progressive debt repayments and accruals being used to meet incremental capex and working capital requirements. Improvement in debt metrics, will nevertheless, remain sensitive to any cost overruns, which may necessitate additional debt funding.

 

Epigral has demonstrated track record in the execution of complex projects such as chloromethanes, CPVC, ECH and hydrogen peroxide over the last three fiscals. It has announced to enter into CPVC compound with a capacity of 35,000 tonne per annum (TPA). This expansion is expected to get commissioned in the fourth quarter of fiscal 2024. Epigral commissioned a 18.34 megawatt (MW) wind solar hybrid power plant in the first quarter of fiscal 2024.. Over the medium term, the company is expected to incur annual capex of Rs 300-350 crore, expected to be funded by a prudent mix of internal accrual and incremental debt.

Analytical Approach

CRISIL Ratings has considered the standalone business and financial risk profiles of Epigral.

 

CRISIL Ratings has also treated the optionally convertible redeemable preference shares (OCRPS) of Rs 135 crore as debt.

Key Rating Drivers & Detailed Description

Strengths:

Steady revenue growth, healthy operating margin and good demand prospects: Revenue visibility over the medium term will be driven by steady demand for caustic soda, hydrogen peroxide and chloromethanes and quick ramp up of upcoming facilities for ECH and CPVC. The company has maintained a comfortable operating margin of over 20% (despite volatility), owing to its integrated operations and low-cost production model. Most of Epigral’s chlorine and hydrogen derivative products such as CMS, ECH and CPVC are aimed at import substitution as domestic capacities are low and there is a demand supply mismatch in these products. This is expected to continue over the medium term as well aiding Epigral’s revenue growth and diversification from downstream products which are the derivatives.

 

Comfortable and improving financial risk profile: The company has healthy capital structure with networth Rs 1105 crore and debt of Rs 969 crore (including Optionally Convertible Preference Share (OCRPS)of Rs 135 crores which was earlier considered as part of networth and term term debt of Rs ~630 crores) as on September 30, 2023 translating into gearing of 0.84 times. Gearing is expected to improve over the near to the medium term with accretion to reserves and gradual reduction in debt levels. EPIGRAL continues to maintain healthy debt protection metrics with adjusted interest coverage of ~6-9 times estimates over a period of fiscals 2024-2027. Further, the capex will be funded with a prudent mix of debt and cash accruals.

 

Weaknesses:

High though moderating dependence on the intensely competitive chlor alkali industry: The chlor alkali industry is intensely competitive and dominated by large players such as Gujarat Alkalis and Chemicals Ltd, DCM Shriram Ltd, Grasim Industries Ltd, and Reliance Industries Ltd (rated ‘CRISIL AAA/Stable/CRISIL A1+’). The top seven players together hold 40-50% of the market share. While Epigral has been growing at a healthy pace and new products will add to revenue visibility further, scale of operations remains moderate compared to peers. Besides, currently around 58% of its revenues are derived from the chlor-alkali segment as on September 30, 2023, especially caustic soda, which is commoditized in nature, and prone to business cycles. Nevertheless, revenue from chlor alkali expected to go down further to ~40% over next 3-4 fiscals with ramp up of downstream facilities.

 

Vulnerability to fluctuations in caustic soda prices and regulatory risk: Profitability of caustic manufacturing companies depends on the prevailing ECU prices. Cyclical downturns or adverse variability in demand-supply balance, may drag down realizations for caustic soda players. The government of India imposed an anti-dumping duty on caustic soda imports from South Korea and China. Hence, prices could come under pressure in the event of increased imports from China, and removal of anti-dumping duty, thus impacting profitability of domestic players including Epigral. The company’s operating margin has been at 22-40% in the past six years, reflective of the aforesaid factors.

 

With EPIGRAL diversifying into downstream chlorine derivative products such as CMS, ECH and CPVC, contribution from caustic soda is expected to reduce in future, which will help in stabilising operating profitability and accruals.

Liquidity: Strong

Liquidity profile of the company is likely to remain strong with expected accruals of Rs 300-400 crores being sufficient to cover repayment obligations of Rs 200-240 crores over the near to the medium term. Further, working capital lines of Rs. 300 crores were utilized 60% on an average over the six months ended October 31, 2023, providing sufficient cushion for meeting incremental working capital requirement and exigencies. Internal accruals and undrawn sanctioned term loan limits should suffice to cover the capex requirements going forward.

Outlook: Stable

CRISIL Ratings believes Epigral’s business risk profile will continue to benefit from the diversity in revenue from downstream derivative products and healthy operating efficiency. While debt levels are likely to peak in fiscal 2024, healthy cash accrual and progressive debt repayment, will help buttress the impact of debt addition for ongoing projects, enabling improvement in debt metrics over the medium term.

Rating Sensitivity Factors

Upward Factors:

  • Improvement in operating performance driven by swift ramp up of new capacities, supporting double digit revenue growth and sustenance of healthy operating margin 
  • Continued improvement in financial profile and debt metrics; for instance, debt/EBITDA remaining at 1.2-1.4 times

 

Downward Factors:

  • Sizeable moderation in operating performance with sustained deterioration in operating margin impacting cash generation
  • Significant delay in commissioning of new capacities or higher-than-expected debt availed for funding the capex leading to deterioration in credit metrics - debt/EBITDA of 2.5-2.7 times on a sustained basis. 

About the Company

Epigral, part of the Ahmedabad-based Meghmani group, was incorporated in September 2007 as a subsidiary of Meghmani Organics Ltd (MOL), to establish a captive source of caustic soda and chlorine derivatives. Pursuant to the National Company Law Tribunal approval for demerger, Epigral was listed on the stock exchanges with the promoters currently holding 71.38% of the equity stake with balance being held by the public.

Key Financial Indicators

Particulars*

Unit

2023

2022

Revenue

Rs.Crore

2166

1554

Profit After Tax (PAT)

Rs.Crore

353

253

PAT Margin

%

16.3

16.3

Adjusted debt/Adjusted networth

Times

0.84

1.42

Interest coverage

Times

10.6

11.60

*CRISIL Ratings adjusted numbers

Any other information: Not Applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs,Crore)

Complexity levels

Rating assigned with outlook

NA

Working capital facility

NA

NA

NA

50.00

NA

CRISIL AA-/Stable

NA

Short Term Loan!

NA

NA

NA

80.00

NA

CRISIL A1+

NA

Packing credit in Foreign currency$

NA

NA

NA

72.00

NA

CRISIL A1+

NA

Letter of Credit^

NA

NA

NA

80.00

NA

CRISIL A1+

NA

Letter of Credit%

NA

NA

NA

100.00

NA

CRISIL A1+

NA

Bank Guarantee&

NA

NA

NA

18.00

NA

CRISIL A1+

NA

Rupee term loan

NA

NA

01-Feb-2025

50

NA

CRISIL AA-/Stable

NA

Rupee term loan

NA

NA

02-Apr-2027

152

NA

CRISIL AA-/Stable

NA

Rupee term loan

NA

NA

29-Mar-2025

39.47

NA

CRISIL AA-/Stable

NA

Rupee term loan

NA

NA

19-Jun-2028

270.51

NA

CRISIL AA-/Stable

NA

Rupee term loan@

NA

NA

08-Sep-2031

75

NA

CRISIL AA-/Stable

NA

Proposed long term bank loan facility#

NA

NA

NA

63.02

NA

CRISIL AA-/Stable

&Fully Interchangeable with Letter of Credit

^Fully Interchangeable with cash credit & working capital demand loan; interchangeable with Bank Guarantee upto Rs.10 crores and Interchangeable with SBLC for Buyers’ Credit up to Rs. 40 crores

%Fully Interchangeable with Cash Credit Limits; interchangeable with Bank Guarantee upto Rs.8 crore & Credit Exposure Limit upto Rs.3 crore

$Fully Interchangeable with cash credit / PSFC / WCDL / EPC / IBD / IBP / FUBD / FBP / LC for Short Term

#Yet to be allocated

@Axis bank is sanction limit Rs.350 cr, out of which company has borrowed Rs.75 Cr as on 30th Sept 2023

!Fully Interchangeable with Pre-shipment financing under export orders / Import LC ; interchangeable with Overdraft facility upto Rs.30 crore & Rs.20 crore ; interchangeable with Bond & Guarantee upto Rs.20 crores; interchangeable with Financial Guarantee upto Rs.15 crore

Annexure - Rating History for last 3 Years
  Current 2024 (History) 2023  2022  2021  Start of 2021
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 852.0 CRISIL A1+ / CRISIL AA-/Stable   -- 24-11-23 CRISIL AA-/Stable 07-12-22 CRISIL AA-/Stable 22-12-21 CRISIL AA-/Stable CRISIL A+/Watch Developing
      --   --   --   -- 01-12-21 CRISIL AA-/Stable CRISIL A+/Watch Developing
      --   --   --   -- 07-05-21 CRISIL A+/Positive --
      --   --   --   -- 27-04-21 CRISIL A+/Positive --
      --   --   --   -- 15-01-21 CRISIL A+/Watch Developing --
Non-Fund Based Facilities ST 198.0 CRISIL A1+   --   --   --   -- --
All amounts are in Rs.Cr.
 
 
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee& 18 ICICI Bank Limited CRISIL A1+
Letter of Credit^ 80 HDFC Bank Limited CRISIL A1+
Letter of Credit% 100 State Bank of India CRISIL A1+
Packing Credit in Foreign Currency$ 72 ICICI Bank Limited CRISIL A1+
Proposed Long Term Bank Loan Facility# 63.02 Not Applicable CRISIL AA-/Stable
Rupee Term Loan@ 75 Axis Bank Limited CRISIL AA-/Stable
Rupee Term Loan 50 HDFC Bank Limited CRISIL AA-/Stable
Rupee Term Loan 152 State Bank of India CRISIL AA-/Stable
Rupee Term Loan 39.47 The Federal Bank Limited CRISIL AA-/Stable
Rupee Term Loan 270.51 HDFC Bank Limited CRISIL AA-/Stable
Short Term Loan! 80 Standard Chartered Bank Limited CRISIL A1+
Working Capital Facility 50 Kotak Mahindra Bank Limited CRISIL AA-/Stable

&Fully Interchangeable with Letter of Credit

^Fully Interchangeable with cash credit & working capital demand loan; interchangeable with Bank Guarantee upto Rs.10 crores and Interchangeable with SBLC for Buyers’ Credit up to Rs. 40 crores

%Fully Interchangeable with Cash Credit Limits; interchangeable with Bank Guarantee upto Rs.8 crore & Credit Exposure Limit upto Rs.3 crore

$Fully Interchangeable with cash credit / PSFC / WCDL / EPC / IBD / IBP / FUBD / FBP / LC for Short Term

#Yet to be allocated

@Axis bank is sanction limit Rs.350 cr, out of which company has borrowed Rs.75 Cr as on 30th Sept 2023

!Fully Interchangeable with Pre-shipment financing under export orders / Import LC ; interchangeable with Overdraft facility upto Rs.30 crore & Rs.20 crore ; interchangeable with Bond & Guarantee upto Rs.20 crores; interchangeable with Financial Guarantee upto Rs.15 crore

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for Chemical Industry

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Poonam Upadhyay
Director
CRISIL Ratings Limited
B:+91 22 3342 3000
poonam.upadhyay@crisil.com


Shubhanshu Singhal
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Shubhanshu.Singhal@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html